Kidney Transplantation Clinical Trial
Official title:
Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study
This project comprises immunological and virological analyses within a prospective clinical study of Rituximab (Rtx)-treated blood group incompatible living donor (LD) renal transplant recipients compared to blood group compatible LD recipients without Rtx induction, and of living donor compared to deceased donor renal transplant recipients treated with tacrolimus (Tacr)/mycophenolate sodium (MPS). Aim of this project is to assess short- and long-term effects of immunosuppressive therapy (Rtx induction) and of living donation on immunological and histological parameters of graft outcome and on viral replication (BK virus (BKV), JC virus (JCV), cytomegalovirus (CMV), Epstein Barr virus (EBV)) with the potential to improve long-term graft outcome and to enable risk estimation of virus disease.
Objective. Blood group incompatible (ABOi) LD renal transplantation represents a recognized
treatment modality in Germany. In this setting, ethical considerations allow for a detailed
study of short- and long-term immunological and virological effects of Rtx induction therapy,
including sequential protocol biopsies. In the proposed project we will perform analyses on
peripheral blood, iliac lymph nodes and protocol biopsies. Protocol biopsies are routinely
obtained 3 and 12 months posttransplant at the Universities of Giessen and Freiburg. In this
prospective, open pilot study, immunological parameters of graft outcome and control of
polyomavirus, EBV and CMV replication will be compared between RTx-treated ABOi LD renal
transplant recipients (n=25-30, group 1) and blood group compatible LD renal transplant
recipients without Rtx induction (n=25-30, group 2) but otherwise comparable
immunosuppressive treatment (MPS and Tacr, switch to Tacr-MR (modified release) within 2
weeks posttransplant; follow-up of 5 years). The same analyses will be done in DD renal
transplant recipients treated with Tacr (switch to Tacr-ME) and MPS (n=25-30, group 3). This
study design allows to analyze the impact of living donation on immunoregulation and virus
control (groups 2 versus 3).
Background. There is growing evidence that humoral mechanisms play a major role in chronic
allograft dysfunction, which was shown to be significantly associated with de-novo formation
of donor-specific antibodies against human leucocyte antigens (HLA). However, B cells appear
to act not only in humoral responses against the graft but may play a significant role in
T-cell mediated antidonor responses due to their role as effective antigen-presenting cells.
This is further suggested by the fact that Rtx is effective in primarily T-cell mediated
diseases such as rheumatoid arthritis or multiple sclerosis.
Hypothesis/specific aims. We hypothesize that Rtx induction may alter immunoregulation short-
and long-term after renal transplantation with the potential to improve long-term outcome.
Graft protective effects of Rtx induction may be provided by B cell depletion and the
resulting effects on humoral as well as T cell responses, and also by altered responses after
B cell repopulation. Possible negative effects of Rtx on polyomavirus and CMV control as well
as protective effects on EBV replication, de-novo monoclonal gammopathy and regulation of
lymphoma growth factors (interleukins 6 and 10 (IL-6, IL-10)) will be analyzed. Furthermore,
B cell subset analysis in peripheral blood and the probably associated impact of Rtx on B
cell depletion in graft draining iliac lymph nodes may enable us to establish an optimized
Rtx dosage and thereby allow successful ABOi renal transplantation without the currently
observed 15% drop outs.
Preliminary results. We have performed clinical studies showing the predictive power of
immune parameters such as regulatory anti-Fab autoantibodies, sCD30, CD4 (cluster of
differentiation 4) helper activity, and CD4 cell IL-4 (interleukin 4) and IL-10 (interleukin
10) responses on graft outcome. The long-term effect of Rtx induction therapy and of living
donation on these parameters will be analyzed.
Previously, we found that patients at risk of polyomavirus nephropathy may be recognized
early posttransplant by sequential reverse transcriptase polymerase chain (rt-PCR) assessment
of polyomavirus replication in urine. Sequential rt-PCR testing of polyomavirus replication
in urine and plasma will be used to analyze effects of Rtx induction on polyomavirus control.
Proposed methods. Immune parameters will be analyzed mainly pretransplant, 3 months and 1, 2
and 5 years posttransplant. Flow cytometry (including regulatory T cells, B cell subsets,
expression of cytokine receptors, costimulatory and adhesion molecules), mitogen-stimulated
allogeneic cocultures, protein-A plaque assay (B cell responses, CD4 helper activity),
intracellular cytokine analysis of CD4+ and CD8+ (cluster of differentiation 8) T cells, B
cells and monocytes, rt-PCR for virological studies (BKV, JCV, CMV, EBV) and
immunofluorescent staining of iliac lymph nodes (obtained at time of transplantation) and
protocol biopsies will be used. Donor-specific antibodies will be detected using
lymphocytotoxicity, HLA class I and II ELISA and Luminex assays. Donor-specificity will be
confirmed by T- and B-cell crossmatch with donor cells. Regulatory IgG (immunoglobulin G) and
IgA (immunoglobulin A) anti-Fab autoantibodies, neopterin and sCD30 will be assessed by
ELISA.
Expected results. We expect that Rtx induction will show an impact on immunological
parameters of graft outcome, such as de-novo posttransplant antidonor HLA antibody formation.
This pilot study may allow for improved long-term kidney graft outcome in recipients with
immunologic risk parameters by virtue of patient-tailored immunosuppressive therapy. In ABOi
renal transplantation, this study may prevent the current 15% drop out rates by allowing an
optimized Rtx dosage based on the intended dose response analysis (B cell subset analysis in
blood and graft draining lymph nodes). Furthermore, this study will allow risk estimation of
Rtx administration with respect to CMV and polyomavirus replication, and may provide clues
concerning protection against EBV replication and posttransplant lymphoproliferative disease.
The latter point is of great clinical importance in patients with an enhanced PTLD
(posttransplant lymphoproliferative disease) risk such as EBV negative recipients of EBV
positive grafts.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |